Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Down 6.23%
As of Tuesday, August 11, Enanta Pharmaceuticals, Inc.’s ENTA share price has dipped by 6.23%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Down 5.72%
As of Friday, July 10, Enanta Pharmaceuticals, Inc.’s ENTA share price has dipped by 5.72%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 5.35%
As of Friday, June 26, Enanta Pharmaceuticals, Inc.’s ENTA share price has surged by 5.35%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 6.09%
As of Thursday, June 04, Enanta Pharmaceuticals, Inc.’s ENTA share price has surged by 6.09%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Down 5.05%
As of Tuesday, June 02, Enanta Pharmaceuticals, Inc.’s ENTA share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $400.4 | $271.6 | 34% |
|
| Shares Out (Mil) | 29.0 | 51.2 | 37% |
|
| Institutional Ownership | 93.6% | 92.3% | 64% |
|
| Float (Mil) | 20.1 | 39.8 | 29% |
|
| Beta | 1.01 | 0.93 | 61% |
|
| Avg Daily Volume (000s) | 171 | 489 | 42% |
|
| Price Change (52-week) |
93.4% | 57.7% | 89% |
|
| Growth | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (11.8%) | 13.6% | 4% |
|
| Net Income (5yr) | (17.7%) | (10.1%) | 22% |
|
| EPS (5yr) | (16.2%) | 16.0% | 17 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.5%) | (15.6%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 4 | 5 | |
| Current EPS | ($0.510) | ($1.880) | ($2.048) | |
| Month Ago EPS | ($0.510) | ($1.880) | ($2.048) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.476) | ($2.036) | ($2.092) | |
| Year/Year Chg | 13.1% | (51.0%) | (50.2%) | |
| Financials | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $69 | $37 | 23% |
|
| Net Income (TTM) (Mil) | ($62) | ($44) | 14% |
|
| EPS (TTM) | ($2.466) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | ($25) | $3 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $151 | $4 | 48% |
|
| Enterprise Value (Q1) (Mil) | $367 | $190 | 32% |
|
| Valuation | ENTA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.43 | 2.82 | 68% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ENTA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 63.8% | 96% |
|
| Net Margin | (89.6%) | (70.6%) | 8% |
|
| ROA | (19.4%) | (49.3%) | 21% |
|
| ROE | (59.0%) | (58.1%) | 14% |
|
| Liabilities to Assets | 63.0% | 30.5% | 57% |
|
| F-Score | 3 | 3 | 19% |
|
Enanta Pharmaceuticals, Inc. did not pass any screens on 8/7/2026.
